|别名||化合物Ixazomib citrate, MLN9708, 枸橼酸艾沙佐米|
Ixazomib citrate is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (IC50 of 3.4 nM ) with potential antineoplastic activity.
20S proteasome β5 20S proteasome β1 20S proteasome β2
Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells.
In animal tumor model studies, MLN2238 is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of MLN2238 versus bortezomib showed a significantly longer survival time in mice treated with MLN2238 than mice receiving bortezomib.
化合物Ixazomib citrate , MLN9708 , 枸橼酸艾沙佐米
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 100 mg/mL (193.38 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
For research use only.